CK levels in unmedicated bipolar patients

European Neuropsychopharmacology

Volumn 17, Issue 12, 2007, Pages 763-767

  Segal, Michael ^a,b   Avital, Avi ^c,d   Drobot, Marina ^a   Lukanin, Aida ^a   Derevenski, Andrei ^a   Sandbank, Sergio ^a   Weizman, Abraham ^e,f  

^a Flugelman's Mazra Mental Health Medical Center   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d THE MAX STERN YEZREEL VALLEY COLLEGE   (Israel)

^e GEHA MENTAL HEALTH CENTER   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bipolar disorder; Creatine kinase; Dopamine; Serotonin

Indexed keywords

CREATINE KINASE; DOPAMINE; SEROTONIN;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DEPRESSION; ENZYME ACTIVITY; FEMALE; HAMILTON SCALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; PRIORITY JOURNAL; RATING SCALE; YOUNG MANIA RATING SCALE;

ADULT; AGED; BIPOLAR DISORDER; CREATINE KINASE; DEPRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 35348891932     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.04.007     Document Type: Article

References (38)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th.Ed. (1994), A.P.A., Washington D.C.
2. Amsterdam J.D., Winokur A., Lucki I., Caroff S., Snyder P., and Rickels K. A neuroendocrine test battery in bipolar patients and healthy subjects. Arch. Gen. Psychiatry 40 (1983) 515-521
3. Andres R.H., Huber A.W., Schlattner U., Perez-Bouza A., Krebs S.H., Seiler R.W., Wallimann T., and Widmer H.R. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience 133 (2005) 701-713
4. Brugue E., and Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog. Neurol. Biol. Psychiatry 31 (2007) 275-282
5. Burklen T.S., and Hirschy A. Brain-type creatine kinase BB-CK interacts with the Golgi Matrix Protein GM130 in early prophase. Mol. Cell. Biochem. 297 (2007) 53-64
6. Cavanaugh J.J., and Finlayson R.E. Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. J. Clin. Psychiatry 45 (1984) 356-357
7. CK, NAC, UV. Liquid Determinazione cinetica UV secondo le recomendazione D6Kc nel siero e nel plasma (1996), Sentinel CH, Milano, Italy
8. Dager S.R., Friedman S.D., Parow A., Demopulos C., Stoll A.L., Lyoo I.K., Dunner D.L., and Renshaw P.F. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch. Gen. Psychiatry 61 (2004) 450-458
9. Gabow P.A., Kaehny W.D., and Kelleher S.P. The spectrum of rhabdomyolysis. Medicine (Baltimore) 61 (1982) 141-152
10. Goode D.J., and Meltzer H.Y. Effects of isometric exercise on serum creatine phosphokinase activity. Arch. Gen. Psychiatry 33 (1976) 1207-1211
11. Hamilton M.A. Rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
12. Kato T., Takahashi S., Shioiri T., and Inubushi T. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J. Affect. Disord. 27 (1993) 53-59
13. Kato T., Takahashi S., Shioiri T., Murashita J., Hamakawa H., and Inubushi T. Reduction of brain phosphocreatine in bipolar II disorder detected byphosphorus-31 magnetic resonance spectroscopy. J. Affect. Disord. 31 (1994) 125-133
14. Lev E.I., Hendler I., Siebner R., Tashma Z., Wiener M., and Tur-Kaspa I. Creatine kinase activity decrease with short-term freezing. Enzyme Protein 48 (1994-1995) 238-242
15. MacDonald M.L., Naydenov A., Chu M., Matzilevich D., and Konradi C. Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord. 8 (2006) 255-264
16. Manor I., Hermesh H., Valevski A., Benjamin Y., Munitz H., and Weizman A. Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis. Biol. Psychiatry 43 (1998) 288-292
17. Mazza M., Satta M.A., Bria P., and Mazza S. Neuroendocrinology of mood disorders. Clin. Ter. 155 (2004) 537-541
18. Melkersson K. Serum creatine kinase levels in chronic psychosis patients-a comparison between atypical and conventional antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 1277-1282
19. Meltzer H. Muscle enzyme release in the acute psychoses. Arch. Gen. Psychiatry 21 (1969) 102-112
20. Meltzer H.Y., and Moline R. Muscle abnormalities in acute psychoses. Arch. Gen. Psychiatry 23 (1970) 481-491
21. Meltzer H.Y., Ross-Stanton J., and Schlessinger S. Mean serum creatine kinase activity in patients with functional psychoses. Arch. Gen. Psychiatry. 37 (1980) 650-655
22. Meltzer H.Y., Cola P.A., and Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15 (1996) 395-405
23. Moller H.J. Bipolar disorder and schizophrenia: distinct illnesses or a continuum?. J. Clin. Psychiatry 64 (2003) 23-27
24. Neumann D., Schlattner U., and Wallimann T. A molecular approach to the concerted action of kinases involved in energy homoeostasis. Biochem. Soc. Trans. 31 (2003) 169-174
25. Randrup A., Munkvad I., and Fog R. Mania, depression and brain dopamine. Current developments in psychopharmacology vol. 2 (1975), Spectrum Press, New Yorkp 206-248
26. Schneider C., Stull G.A., and Apple F.S. Kinetic characterization of human heart and skeletal muscle CK isoenzymes. Enzyme 39 (1988) 220-226
27. Segal M., Avital A., Drobot M., Lukanin A., Derevenski A., Sandbank S., and Weizman A. Serum creatine kinase level in unmedicated nonpsychotic, psychotic, bipolar and schizoaffective depressed patients. Eur. Neuropsychopharmacol. 17 (2007) 194-198
28. Soni S.D. Serum creatine phosphokinase in acute psychosis. Br. J. Psychiatry 128 (1976) 181-183
29. Takubo H., Shimoda-Matsubayashi S., and Mizuno Y. Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study. Parkinsonism Relat. Disord. 9 (2003) 43-46
30. Taylor J.R., and Abichandani L. Creatine phosphokinase elevations and psychiatric symptomatology. Biol. Psychiatry 15 (1980) 865-870
31. Terao T., Matsuda S., Kojima H., Okuno K., Hori H., Kaku A., Ueda N., and Etoh A. Incidence and risk factors of benign creatine phosphokinase elevations in chronic psychiatric patients. Neuropsychobiology 39 (1999) 173-180
32. Vale S., Espejel M.A., Calcaneo F., Ocampo J., and Diaz-de-Leon J. Creatine phosphokinase. Increased activity of the spinal fluid in psychotic patients. Arch. Neurol. 30 (1974) 103-104
33. Wallimann T., Wyss M., Brdiczka D., Nicolay K., and Eppenberger H.M. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem. J. 281 (1992) 21-40
34. Wilhelm K., Curtis J., Birkett V., and Kenney-Herbert J. The clinical significance of serial creatine phosphokinase estimations in acute ward admissions. Aust. N. Z. J. Psychiatry 28 (1994) 453-457
35. Wood J.G., Joyce P.R., Miller A.L., Mulder R.T., and Kennedy M.A. A polymorphism in the dopamine beta-hydroxylase gene is associated with "paranoid ideation" in patients with major depression. Biol. Psychiatry 51 (2002) 365-369
36. Wyss M., and Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 80 (2000) 1107-1213
37. Yildiz-Yesiloglu A., and Ankerst D.P. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 969-995
38. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978) 429-435